{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:17:15Z","timestamp":1789906635147,"version":"4.0.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2020,6,2]]},"DOI":"10.3233\/jnd-190464","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T11:38:13Z","timestamp":1590147493000},"page":"269-277","source":"Crossref","is-referenced-by-count":15,"title":["Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series"],"prefix":"10.1177","volume":"7","author":[{"given":"Sorabh","family":"Datta","sequence":"first","affiliation":[{"name":"University of Missouri Health Care, Columbia, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivangi","family":"Singh","sequence":"additional","affiliation":[{"name":"University of Missouri Health Care, Columbia, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"University of Missouri Health Care, Columbia, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JND-190464_ref1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48-49","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"issue":"26","key":"10.3233\/JND-190464_ref2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.3233\/JND-190464_ref3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis \u2013autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.3233\/JND-190464_ref4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.3233\/JND-190464_ref5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.3233\/JND-190464_ref6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.3233\/JND-190464_ref7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: A clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J Neurol"},{"issue":"1","key":"10.3233\/JND-190464_ref8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/joim.12163","article-title":"Pathogenic immune mechanisms at the neuromuscular synapse: The role of specific antibody-binding epitopes in myasthenia gravis","volume":"275","author":"Huijbers","year":"2014","journal-title":"J Intern Med"},{"issue":"10","key":"10.3233\/JND-190464_ref9","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.3233\/JND-190464_ref10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"issue":"3","key":"10.3233\/JND-190464_ref11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"issue":"3","key":"10.3233\/JND-190464_ref12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"issue":"2","key":"10.3233\/JND-190464_ref13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ncl.2018.01.004","article-title":"Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies","volume":"36","author":"Rivner","year":"2018","journal-title":"Neurol Clin"},{"key":"10.3233\/JND-190464_ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09498-4"},{"issue":"1","key":"10.3233\/JND-190464_ref15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.3233\/JND-190464_ref16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/1744666X.4.1.43","article-title":"Effect of complement and its regulation on myasthenia gravis pathogenesis","volume":"4","author":"Kusner","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.3233\/JND-190464_ref20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","article-title":"A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis","volume":"48","author":"Howard","year":"2013","journal-title":"Muscle Nerve"},{"issue":"17-18","key":"10.3233\/JND-190464_ref21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"issue":"7","key":"10.3233\/JND-190464_ref22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JND-190464_ref23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: Comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"J Clin Neuromuscul Dis"},{"issue":"1","key":"10.3233\/JND-190464_ref24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mus.24929","article-title":"Correlation of single-breath count test and neck flexor muscle strength with spirometry in myasthenia gravis","volume":"53","author":"Elsheikh","year":"2016","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.3233\/JND-190464_ref25","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: A randomized double-blind clinical trial","volume":"62","author":"Gajdos","year":"2005","journal-title":"Arch Neurol"},{"issue":"5","key":"10.3233\/JND-190464_ref26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: Still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.3233\/JND-190464_ref27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: An update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.3233\/JND-190464_ref29","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JND-190464_ref30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IJGM.S88552","article-title":"Animal models of myasthenia gravis: Utility and limitations","volume":"9","author":"Mantegazza","year":"2016","journal-title":"Int J Gen Med"},{"issue":"6","key":"10.3233\/JND-190464_ref31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.imbio.2015.04.006","article-title":"The membrane attack complex as an inflammatory trigger","volume":"221","author":"Morgan","year":"2016","journal-title":"Immunobiology"},{"issue":"Pt 7","key":"10.3233\/JND-190464_ref32","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"3","key":"10.3233\/JND-190464_ref33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"issue":"5-6","key":"10.3233\/JND-190464_ref34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/08916930903541208","article-title":"Diagnostic use of autoantibodies in myasthenia gravis","volume":"43","author":"Leite","year":"2010","journal-title":"Autoimmunity"},{"issue":"1","key":"10.3233\/JND-190464_ref35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.3233\/JND-190464_ref36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1413","author":"Cossins","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.3233\/JND-190464_ref37","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol"},{"key":"10.3233\/JND-190464_ref38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1196\/annals.1405.020","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies","volume":"1132","author":"Vincent","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"10.3233\/JND-190464_ref39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Ann Neurol"},{"issue":"51","key":"10.3233\/JND-190464_ref41","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.3233\/JND-190464_ref42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.3233\/JND-190464_ref43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.3233\/JND-190464_ref44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.3233\/JND-190464_ref45","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.3233\/JND-190464_ref46","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","article-title":"Eculizumab: A review in generalized myasthenia gravis","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-190464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:27Z","timestamp":1777506567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-190464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":41,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jnd-190464","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}